Financials in USD. Standardized financial statements.
A compact view of how Teva Pharmaceutical Industries Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B | $16.66B | $16.89B | $18.85B | $22.39B | $21.90B |
| Revenue Growth? | +4.3% | +4.4% | +6.2% | -6.0% | -4.7% | -1.4% | -10.4% | -15.8% | +2.2% | 0.0% |
| Cost of Revenue? | $8.32B | $8.48B | $8.20B | $7.95B | $8.28B | $8.93B | $9.35B | $10.56B | $11.56B | $10.04B |
| Gross Profit? | $8.94B | $8.06B | $7.64B | $6.97B | $7.59B | $7.73B | $7.54B | $8.30B | $10.82B | $11.86B |
| Gross Margin? | +51.8% | +48.7% | +48.2% | +46.7% | +47.8% | +46.4% | +44.6% | +44.0% | +48.4% | +54.1% |
| Operating Expenses? | $6.78B | $8.37B | $7.21B | $9.17B | $5.88B | $11.30B | $7.98B | $5.43B | $6.83B | $7.21B |
| Operating Income? | $2.16B | -$303.00M | $433.00M | -$2.20B | $1.72B | -$3.57B | -$443.00M | -$1.64B | -$17.48B | $2.15B |
| EBITDA? | $3.14B | $4.43B | $1.56B | -$925.00M | $4.41B | $4.61B | $4.44B | $186.00M | -$15.52B | $2.87B |
| Income Before Tax | $1.24B | -$1.28B | -$622.00M | -$3.14B | $667.00M | -$3.93B | -$723.00M | -$2.60B | -$18.38B | $824.00M |
| Income Tax Expense | -$180.00M | $676.00M | -$7.00M | -$643.00M | $211.00M | $168.00M | $278.00M | -$195.00M | -$1.93B | $521.00M |
| Net Income? | $1.41B | -$1.64B | -$559.00M | -$2.45B | $417.00M | -$3.99B | -$999.00M | -$2.15B | -$16.27B | $329.00M |
| EPS? | $1.23 | $-1.45 | $-0.50 | $-2.20 | $0.38 | $-3.64 | $-0.92 | $-2.11 | $-16.01 | $0.07 |
| Diluted EPS? | $1.20 | $-1.45 | $-0.50 | $-2.20 | $0.38 | $-3.64 | $-0.92 | $-2.11 | $-16.01 | $0.07 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality